104 related articles for article (PubMed ID: 34997872)
1. In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors.
Fiori-Duarte AT; de Oliveira Guarnieri JP; de Oliveira Borlot JRP; Lancellotti M; Rodrigues RP; Kitagawa RR; Kawano DF
Mol Divers; 2022 Dec; 26(6):3365-3378. PubMed ID: 34997872
[TBL] [Abstract][Full Text] [Related]
2. Engineering resveratrol-loaded chitosan nanoparticles for potential use against Helicobacter pylori infection.
Spósito L; Fonseca D; Gonçalves Carvalho S; Sábio RM; Marena GD; Bauab TM; Bagliotti Meneguin A; Parreira P; L Martins MC; Chorilli M
Eur J Pharm Biopharm; 2024 Jun; 199():114280. PubMed ID: 38588828
[TBL] [Abstract][Full Text] [Related]
3. Cinnamaldehyde: An effective component of Cinnamomum cassia inhibiting Helicobacter pylori.
Li CY; Liao LJ; Yang SX; Wang LY; Chen H; Luo P; Huang GR; Huang YQ
J Ethnopharmacol; 2024 Aug; 330():118222. PubMed ID: 38663778
[TBL] [Abstract][Full Text] [Related]
4. Alanine racemase a promising Helicobacter pylori drug target inhibited by propanoic acid.
Ibrahim KA; El-Ashrey MK; Kashef MT; Helmy OM
Microbes Infect; 2023; 25(7):105167. PubMed ID: 37271368
[TBL] [Abstract][Full Text] [Related]
5. Studies on Methylpyrazole-Substituted Benzimidazoles to Target
Dilip H; Thiruvenkatam V; Kirubakaran S
ACS Infect Dis; 2024 Jun; 10(6):2262-2275. PubMed ID: 38787329
[TBL] [Abstract][Full Text] [Related]
6. Lyophilized cell-free supernatants of Limosilactobacillus fermentum T0701 exhibited antibacterial activity against Helicobacter pylori.
Sornsenee P; Surachat K; Wong T; Kaewdech A; Saki M; Romyasamit C
Sci Rep; 2024 Jun; 14(1):13632. PubMed ID: 38871850
[TBL] [Abstract][Full Text] [Related]
7. CuO nanoparticles for green synthesis of significant anti-Helicobacter pylori compounds with in silico studies.
Shehab WS; Elsayed DA; Abdel Hamid AM; Assy MG; Mouneir SM; Hamed EO; Mousa SM; El-Bassyouni GT
Sci Rep; 2024 Jan; 14(1):1608. PubMed ID: 38238369
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening and molecular dynamics simulations of natural products targeting LuxS/AI-2 system as a novel antibacterial strategy for antibiotic resistance in
Ashok AK; Gnanasekaran TS; Santosh Kumar HS; Srikanth K; Prakash N; Gollapalli P
J Biomol Struct Dyn; 2024 Apr; 42(6):2913-2928. PubMed ID: 37160706
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Virtual Screening of Helicobacter pylori SecA Inhibitors.
Jian T; Su Q; Liu Y; Seoh HK; Houghton JE; Tai PC; Huang X
IEEE Trans Nanobioscience; 2023 Oct; 22(4):933-942. PubMed ID: 37030876
[TBL] [Abstract][Full Text] [Related]
10. Aspects for development of novel antibacterial medicines using a vitamin D
Wanibuchi K; Hosoda K; Amgalanbaatar A; Ihara M; Takezawa M; Sakai Y; Masui H; Shoji M; Hayashi S; Shimomura H
J Antibiot (Tokyo); 2023 Nov; 76(11):665-672. PubMed ID: 37658133
[TBL] [Abstract][Full Text] [Related]
11. Anti-Helicobacter pylori activity of swertianolin, isolated from swertia herb.
Suzuki R; Yumoto R; Shirai H; Tanaka T
J Nat Med; 2023 Sep; 77(4):1005-1008. PubMed ID: 37382767
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Docking Studies and Evaluation of Chalcones as Anti-Helicobacter pylori and antitumoral Agents.
Pereira de Oliveira Borlot JR; Schlittler Dos Santos L; Schwarzt Sampaio GJ; Santos Borges A; Rodrigues RP; de Cássia Ribeiro Gonçalves R; Bezerra Dos Santos R; Kitagawa RR
Chem Biodivers; 2023 Oct; 20(10):e202301066. PubMed ID: 37646700
[TBL] [Abstract][Full Text] [Related]
13. In silico identification and analysis of potential inhibitors for acid phosphatase, HppA from Helicobacter pylori.
Sisodia R; Mazumdar PA; Madhurantakam C
J Mol Recognit; 2023 Sep; 36(9):e3049. PubMed ID: 37553866
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic inhibition of gastric cancer-associated bacteria
Akash S; Bayıl I; Mahmood S; Mukerjee N; Mili TA; Dhama K; Rahman MA; Maitra S; Mohany M; Al-Rejaie SS; Ali N; Semwal P; Sharma R
Heliyon; 2023 Oct; 9(10):e20670. PubMed ID: 37876433
[TBL] [Abstract][Full Text] [Related]
15. Anti-
Kang DM; Khalil AAK; Park WS; Kim HJ; Akter KM; Bae JY; Mehtap Büyüker S; Kim JH; Kang KK; Ahn MJ
ACS Omega; 2023 Nov; 8(45):42548-42554. PubMed ID: 38024697
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biological Evaluation of Carvacrol-Based Derivatives as Dual Inhibitors of
Sisto F; Carradori S; Guglielmi P; Traversi CB; Spano M; Sobolev AP; Secci D; Di Marcantonio MC; Haloci E; Grande R; Mincione G
Pharmaceuticals (Basel); 2020 Nov; 13(11):. PubMed ID: 33228095
[TBL] [Abstract][Full Text] [Related]
17. Exploring the inhibitory potential of
Roszczenko-Jasińska P; Giełdoń A; Mazur D; Spodzieja M; Plichta M; Czaplewski C; Bal W; Jagusztyn-Krynicka EK; Bartosik D
Front Mol Biosci; 2023; 10():1335704. PubMed ID: 38274095
[No Abstract] [Full Text] [Related]
18. Molecular analysis of dUTPase of
Sisodia R; Sarmadhikari D; Mazumdar PA; Asthana S; Madhurantakam C
J Biomol Struct Dyn; 2023 Aug; ():1-26. PubMed ID: 37587906
[TBL] [Abstract][Full Text] [Related]
19. Identification of Potential Drug Targets in
Ibrahim KA; Helmy OM; Kashef MT; Elkhamissy TR; Ramadan MA
Pathogens; 2020 Sep; 9(9):. PubMed ID: 32932580
[TBL] [Abstract][Full Text] [Related]
20. Brasiliensic acid:
Lemos LMS; Ọlọ Ba-Whẹ Nù OA; Olasupo IA; Balogun SO; Macho A; Pavan E; de Oliveira Martins DT
J Biomol Struct Dyn; 2023 Dec; ():1-14. PubMed ID: 38054294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
